| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
3,280,000 |
| Market
Cap: |
1.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3437 - $4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. Co.'s primary investigational product is the LOMECEL-B™ cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. Co. is sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome, and hypoplastic left heart syndrome.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
297,872 |
322,872 |
322,872 |
322,872 |
| Total Buy Value |
$699,999 |
$734,301 |
$734,301 |
$734,301 |
| Total People Bought |
3 |
6 |
6 |
6 |
| Total Buy Transactions |
5 |
9 |
9 |
9 |
| Total Shares Sold |
0 |
0 |
23,532 |
219,987 |
| Total Sell Value |
$0 |
$0 |
$81,541 |
$1,060,824 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
3 |
10 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• – – |
2023-08-18 |
4 |
D |
$3.25 |
$13,949 |
D/D |
(4,292) |
41,889 |
|
- |
|
| Lehr Paul T |
General Counsel, Secretary |
• – – |
2023-08-18 |
4 |
D |
$3.25 |
$2,493 |
D/D |
(767) |
142,213 |
|
- |
|
| Agafonova Nataliya |
Chief Medical Officer |
• – – |
2023-08-18 |
4 |
D |
$3.36 |
$10,352 |
D/D |
(3,081) |
26,919 |
|
- |
|
| Locklear Lisa |
Chief Financial Officer |
• – – |
2023-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
|
- |
|
| Agafonova Nataliya |
Chief Medical Officer |
• – – |
2023-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Clavijo James |
CFO and Treasurer |
• – – |
2023-06-29 |
4 |
S |
$3.51 |
$17,550 |
D/D |
(5,000) |
47,303 |
|
43% |
|
| Clavijo James |
CFO and Treasurer |
• – – |
2023-06-28 |
4 |
S |
$3.43 |
$34,300 |
D/D |
(10,000) |
52,303 |
|
43% |
|
| Clavijo James |
CFO and Treasurer |
• – – |
2023-06-27 |
4 |
S |
$3.48 |
$29,691 |
D/D |
(8,532) |
62,303 |
|
40% |
|
| Pfeffer Jeffrey |
|
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Baluch Khoso |
|
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Clavijo James |
CFO and Treasurer |
• – – |
2023-06-02 |
4 |
D |
$3.42 |
$2,572 |
D/D |
(752) |
70,835 |
|
- |
|
| Lehr Paul T |
General Counsel, Secretary |
• – – |
2023-06-02 |
4 |
D |
$3.25 |
$10,553 |
D/D |
(3,247) |
142,980 |
|
- |
|
| Clavijo James |
CFO and Treasurer |
• – – |
2023-06-02 |
4 |
D |
$3.25 |
$10,553 |
D/D |
(3,247) |
71,587 |
|
- |
|
| Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• – – |
2023-04-05 |
4 |
D |
$2.61 |
$9,968 |
D/D |
(3,819) |
46,181 |
|
- |
|
| Lehr Paul T |
General Counsel, Secretary |
• – – |
2023-04-03 |
4 |
D |
$2.61 |
$2,127 |
D/D |
(815) |
146,227 |
|
- |
|
| Clavijo James |
CFO and Treasurer |
• – – |
2023-04-03 |
4 |
D |
$2.61 |
$2,127 |
D/D |
(815) |
74,834 |
|
- |
|
| Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Hare Joshua |
Chief Scientific Officer |
• • • |
2023-01-27 |
4 |
AS |
$4.28 |
$85,600 |
D/D |
(20,000) |
7,793,263 |
|
-16% |
|
| Lehr Paul T |
General Counsel, Secretary |
• – – |
2023-01-03 |
4 |
D |
$3.37 |
$4,961 |
D/D |
(1,472) |
147,042 |
|
- |
|
| Clavijo James |
CFO and Treasurer |
• – – |
2023-01-03 |
4 |
D |
$3.37 |
$4,341 |
D/D |
(1,288) |
75,649 |
|
- |
|
| Hare Joshua |
Chief Scientific Officer |
• • • |
2022-12-02 |
4 |
AS |
$3.74 |
$74,800 |
D/D |
(20,000) |
7,813,263 |
|
-27% |
|
| Hare Joshua |
Chief Scientific Officer |
• • • |
2022-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
48,140 |
7,861,403 |
|
- |
|
| Hare Joshua |
Chief Scientific Officer |
• • • |
2022-10-12 |
4 |
S |
$3.61 |
$361,000 |
D/D |
(100,000) |
7,813,263 |
|
1% |
|
| Lehr Paul T |
General Counsel, Secretary |
• – – |
2022-10-03 |
4 |
D |
$3.75 |
$5,381 |
D/D |
(1,435) |
148,514 |
|
- |
|
| Clavijo James |
CFO and Treasurer |
• – – |
2022-10-03 |
4 |
D |
$3.75 |
$4,710 |
D/D |
(1,256) |
76,937 |
|
- |
|
64 Records found
|
|
Page 2 of 3 |
|
|
